Trial Profile
I-131 therapy for thyroid cancer with recombinant human thyroid-stimulating hormone (Thyrogen)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2011
Price :
$35
*
At a glance
- Drugs Thyrotropin alfa (Primary) ; Iodine-131
- Indications Thyroid cancer
- Focus Biomarker; Therapeutic Use
- 03 Dec 2011 Status changed from active, no longer recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 02 Dec 2011 Planned number of patients 1 added as reported by University Hospital Medical Information Network - Japan.
- 03 Jun 2011 New trial record